How Is Biogen's Stock Performance Compared to Other Biotech Stocks?

With a market cap of $21 billion, Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States and globally. 

Companies worth $10 billion or more are generally described as "large-cap stocks," BIIB fits this bill perfectly. As a leading biotech company, BIIB benefits from an impressive pipeline of drugs including TECFIDERA, VUMERITY, AVONEX, SPINRAZA, SKYCLARYS, and QALSODY.